Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Mass Spectrometry Technology Maps Chemicals as They Migrate Into Skin

By BiotechDaily International staff writers
Posted on 14 May 2014
A mass spectrometry technique gaining acceptance for medical applications such as imaging tumor surfaces can also be used to analyze the migration of small-molecule compounds applied to the skin. Because skin is such a complicated organ, the technology could be a helpful for developing transdermal drugs.

The study’s findings were published April 28, 2014, in the Journal of the American Chemical Society. Stanford University (Stanford, CA, USA) chemistry Profs. Richard N. Zare and Justin Du Bois, postdoc Livia S. Eberlin, graduate student John V. Mulcahy, and colleagues revealed that desorption electrospray ionization-mass spectrometry (DESI-MS) imaging has many advantages over other approaches that require complicated preparation of skin samples.

Moreover, DESI-MS imaging can be performed under ambient settings, instead of in a vacuum condition, as other MS methods require. Furthermore, test compounds do not have to be radioactively labeled or tagged with unwieldy dye molecules that could affect the compounds’ normal migration through skin. “That’s why this method is very appealing,” said Mark R. Prausnitz, a chemical and biomolecular engineering professor who heads the Laboratory for Drug Delivery at Georgia Institute of Technology (Atlanta, GA, USA).

DESI-MS was developed 10 years ago and involves spraying charged solvent droplets at a surface. Backsplash droplets containing dissolved molecules are then captured and examined using a mass spectrometer. The technology has been used for medical applications such as imaging drugs in tissue samples.

The Stanford scientists chose a number of small molecules that change sodium channels in skin cells, including lidocaine and a shellfish toxin. They applied them to the surface of skin samples and were able to track the compounds’ migration to a depth of 1.2 mm.

Such studies of drug migration are required to enlarge the limited selection of transdermal drugs, according to Prof. Prausnitz. Only approximately 30 agents, such as nicotine, have transdermal versions. The drugs must be small, lipophilic, and effective at a low dose. With this newly adapted tool, however, scientists could more readily study methods to enhance skin permeation, Prof. Prausnitz reported. “We’re very interested in the pathway--which part of the skin did the drug go through?”

Related Links:

Stanford University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal bacteria; magnification 1150x (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Infection by Meningitis Bacteria Depends on Dimerization State of Certain Host Cell Proteins

A team of molecular microbiologists has untangled the complex three-way interaction between the non-integrin laminin receptor (LAMR1), galectin-3 (Gal-2), and the pathogenic bacterium Neisseria meningitidis.... Read more

Drug Discovery

view channel

Molecule in Green Tea Used as Carrier for Anticancer Proteins

A molecule that is a key ingredient in green tea can be employed as a carrier for anticancer proteins, forming a stable and effective therapeutic nanocomplex. This new discovery could help to construct better drug-delivery systems. Some cancer treatments depend on medication comprising the therapeutic drug and a carrier... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.